Add Formweb to your mobile device
System Formulary Update
Antiprotozoal Agents (Misc.)
Situation
The antiprotozoal agents (misc.) class review standardization was approved in April 2023.
Background
The following products were reviewed: atovaquone oral suspension, benznidazole tablets, fexinidazole tablets, metronidazole tablets, metronidazole capsules, metronidazole oral suspension, metronidazole solution for injection, miltefosine capsules, nifurtimox tablets, nitazoxanide tablets, nitazoxanide oral suspension, pentamidine oral inhalation, pentamidine solution for injection, secnidazole oral granules, tinidazole tablets.
Assessment/Recommendations
System P&T voted to include the following products on the UNC Health System Drug Formulary:
- Atovaquone 150 mg/mL oral suspension
- Metronidazole 250 mg tablets
- Metronidazole 500 mg tablets
- Metronidazole 50 mg/mL oral suspension (extemporaneous)
- Metronidazole 5 mg/mL (100 mL) solution for injection
- Miltefosine 50 mg capsules
- Pentamidine 300 mg oral inhalation
- Pentamidine 300 mg solution for injection
As a result, the following products will be removed from the inpatient drug formulary:
- Nitazoxanide 500 mg tablets
Note: Stock of this formulary product may vary at individual entities
Formulary/Epic changes will Go-Live on Tuesday, June 20, 2023.